Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
At The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Marina Frimer, MD, associate chief of Research & Academic Development Central Region, and associate professor at the Donald and Barbara Zucker School of Medicine at Hofsta/Nortwell Health in New Hyde Park, New York, about recruiting patients to a trial (NCT04080284) examining maintenance niraparib (Zejula) for platinum-sensitive recurrent uterine cancer.
For [patients with] uterine serous cancer, we have an option for trastuzumab [Herceptin] in women who have a HER2 mutation. However, in women who don’t [harbor a mutation we don’t] have any other maintenance therapy options available at this time. For those patients, we are able to discuss the trial participation.
We really want to open this trial so that other [clinicians can send patients who] may potentially fit the criteria. Given the rarity of the tumor type, it’s very difficult to recruit patients to this trial. We’re really hoping to increase our publicity at the meeting.
Frimer M, Nizam A, Sison C, et al. Phase II trial of maintenance niraparib in patients with stage III, stage IV or platinum-sensitive recurrent uterine serous carcinoma. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.